10X Genomics, Inc. (TXG)
54.15
-3.23
(-5.63%)
USD |
NASDAQ |
Nov 20, 10:00
10X Genomics Cash from Operations (Quarterly) : 15.83M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 15.83M |
| June 30, 2026 | 16.97M |
| March 31, 2026 | 26.12M |
| December 31, 2025 | 40.78M |
| September 30, 2025 | 43.21M |
| June 30, 2025 | 17.71M |
| March 31, 2025 | 34.35M |
| December 31, 2024 | -6.748M |
| September 30, 2024 | 21.64M |
| June 30, 2024 | 7.496M |
| March 31, 2024 | -15.72M |
| December 31, 2023 | 25.76M |
| September 30, 2023 | -25.30M |
| June 30, 2023 | -11.53M |
| March 31, 2023 | -4.125M |
| Date | Value |
|---|---|
| December 31, 2022 | 13.72M |
| September 30, 2022 | -9.564M |
| June 30, 2022 | -16.96M |
| March 31, 2022 | -20.80M |
| December 31, 2021 | 5.805M |
| September 30, 2021 | -26.22M |
| June 30, 2021 | 3.12M |
| March 31, 2021 | -4.082M |
| December 31, 2020 | -130.18M |
| September 30, 2020 | -55.63M |
| June 30, 2020 | -29.52M |
| March 31, 2020 | -2.576M |
| December 31, 2019 | 6.70M |
| September 30, 2019 | 14.53M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Twist Bioscience Corp. | -0.173M |
| Tempus AI, Inc. | 8.618M |
| Intellia Therapeutics, Inc. | -85.43M |
| Personalis, Inc. | -27.07M |
| Alamar Biosciences, Inc. (California) | -14.73M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.503M |
| Cash from Financing (Quarterly) | 8.526M |
| Free Cash Flow | 93.77M |
| Free Cash Flow Per Share (Quarterly) | 0.1136 |
| Free Cash Flow to Equity (Quarterly) | 17.87M |
| Free Cash Flow to Firm (Quarterly) | 14.86M |
| Free Cash Flow Yield | 1.32% |